FLAIR: A Phase II, Open Label, Randomized Study of Osimertinib Plus Bevacizumab Versus Osimertinib in Recurrent or Metastatic Treatment-Naïve NSCLC Patients Harboring EGFR 21L858R Mutation.
Saved in:
| Title: | FLAIR: A Phase II, Open Label, Randomized Study of Osimertinib Plus Bevacizumab Versus Osimertinib in Recurrent or Metastatic Treatment-Naïve NSCLC Patients Harboring EGFR 21L858R Mutation. |
|---|---|
| Authors: | Zhou Q; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China., Li J; Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University, Beijing, China., Cang SD; Department of Medical Oncology, Henan Provincial People's Hospital, Zhengzhou, China., Lin JX; Pulmonary Medicine, Guangdong Provincial People's Hospital, Southern Medical University, Guangzhou, China., Tu HY; Pulmonary Medicine, Guangdong Provincial People's Hospital, Southern Medical University, Guangzhou, China., Du Y; Department of Medical Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China., Qin JW; Respiratory Medicine, Tianjin Chest Hospital, Tianjin, China., Liang XH; Department of Oncology, Huashan Hospital, Fudan University, Shanghai, China., Yu Y; Respiratory Medicine, Harbin Medical University Cancer Hospital, Harbin, China., Lan HT; Department of Medical Oncology, Sichuan Provincial People's Hospital, Sichuan Academy of Medical Sciences, School of Medicine UESTC, Chengdu, China., Shi HQ; Department of Medical Oncology, First Affiliated Hospital of Gannan Medical University, Ganzhou, China., Hua D; Department of Medical Oncology, Wuxi People's Hospital, Wuxi, China., Liu SM; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China; Chinese Thoracic Oncology Group (CTONG), Guangzhou, China., Wu YL; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China. Electronic address: syylwu@live.cn. |
| Source: | Clinical lung cancer [Clin Lung Cancer] 2025 Mar; Vol. 26 (2), pp. 152-157.e1. Date of Electronic Publication: 2024 Sep 20. |
| Publication Type: | Clinical Trial Protocol; Journal Article |
| Journal Info: | Publisher: Elsevier Country of Publication: United States NLM ID: 100893225 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0690 (Electronic) Linking ISSN: 15257304 NLM ISO Abbreviation: Clin Lung Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 39424513 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: FLAIR: A Phase II, Open Label, Randomized Study of Osimertinib Plus Bevacizumab Versus Osimertinib in Recurrent or Metastatic Treatment-Naïve NSCLC Patients Harboring EGFR 21L858R Mutation. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Zhou+Q%22">Zhou Q</searchLink>; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.<br /><searchLink fieldCode="AU" term="%22Li+J%22">Li J</searchLink>; Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University, Beijing, China.<br /><searchLink fieldCode="AU" term="%22Cang+SD%22">Cang SD</searchLink>; Department of Medical Oncology, Henan Provincial People's Hospital, Zhengzhou, China.<br /><searchLink fieldCode="AU" term="%22Lin+JX%22">Lin JX</searchLink>; Pulmonary Medicine, Guangdong Provincial People's Hospital, Southern Medical University, Guangzhou, China.<br /><searchLink fieldCode="AU" term="%22Tu+HY%22">Tu HY</searchLink>; Pulmonary Medicine, Guangdong Provincial People's Hospital, Southern Medical University, Guangzhou, China.<br /><searchLink fieldCode="AU" term="%22Du+Y%22">Du Y</searchLink>; Department of Medical Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.<br /><searchLink fieldCode="AU" term="%22Qin+JW%22">Qin JW</searchLink>; Respiratory Medicine, Tianjin Chest Hospital, Tianjin, China.<br /><searchLink fieldCode="AU" term="%22Liang+XH%22">Liang XH</searchLink>; Department of Oncology, Huashan Hospital, Fudan University, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Yu+Y%22">Yu Y</searchLink>; Respiratory Medicine, Harbin Medical University Cancer Hospital, Harbin, China.<br /><searchLink fieldCode="AU" term="%22Lan+HT%22">Lan HT</searchLink>; Department of Medical Oncology, Sichuan Provincial People's Hospital, Sichuan Academy of Medical Sciences, School of Medicine UESTC, Chengdu, China.<br /><searchLink fieldCode="AU" term="%22Shi+HQ%22">Shi HQ</searchLink>; Department of Medical Oncology, First Affiliated Hospital of Gannan Medical University, Ganzhou, China.<br /><searchLink fieldCode="AU" term="%22Hua+D%22">Hua D</searchLink>; Department of Medical Oncology, Wuxi People's Hospital, Wuxi, China.<br /><searchLink fieldCode="AU" term="%22Liu+SM%22">Liu SM</searchLink>; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China; Chinese Thoracic Oncology Group (CTONG), Guangzhou, China.<br /><searchLink fieldCode="AU" term="%22Wu+YL%22">Wu YL</searchLink>; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China. Electronic address: syylwu@live.cn. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22100893225%22">Clinical lung cancer</searchLink> [Clin Lung Cancer] 2025 Mar; Vol. 26 (2), pp. 152-157.e1. <i>Date of Electronic Publication: </i>2024 Sep 20. – Name: TypePub Label: Publication Type Group: TypPub Data: Clinical Trial Protocol; Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>100893225 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1938-0690 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2215257304%22">15257304 </searchLink><i>NLM ISO Abbreviation: </i>Clin Lung Cancer <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39424513 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.cllc.2024.09.002 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 152 Titles: – TitleFull: FLAIR: A Phase II, Open Label, Randomized Study of Osimertinib Plus Bevacizumab Versus Osimertinib in Recurrent or Metastatic Treatment-Naïve NSCLC Patients Harboring EGFR 21L858R Mutation. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Zhou Q – PersonEntity: Name: NameFull: Li J – PersonEntity: Name: NameFull: Cang SD – PersonEntity: Name: NameFull: Lin JX – PersonEntity: Name: NameFull: Tu HY – PersonEntity: Name: NameFull: Du Y – PersonEntity: Name: NameFull: Qin JW – PersonEntity: Name: NameFull: Liang XH – PersonEntity: Name: NameFull: Yu Y – PersonEntity: Name: NameFull: Lan HT – PersonEntity: Name: NameFull: Shi HQ – PersonEntity: Name: NameFull: Hua D – PersonEntity: Name: NameFull: Liu SM – PersonEntity: Name: NameFull: Wu YL IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 03 Text: 2025 Mar Type: published Y: 2025 Identifiers: – Type: issn-electronic Value: 1938-0690 Numbering: – Type: volume Value: 26 – Type: issue Value: 2 Titles: – TitleFull: Clinical lung cancer Type: main |
| ResultId | 1 |
